AbCellera Biologics Inc.
ABCL
$2.60
$0.072.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -44.98% | -1.39% | -27.18% | -18.36% | -57.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.98% | -1.39% | -27.18% | -18.36% | -57.40% |
| Cost of Revenue | -5.24% | 8.05% | 12.21% | -25.38% | 63.17% |
| Gross Profit | -4.01% | -10.04% | -27.21% | 27.49% | -377.87% |
| SG&A Expenses | 0.47% | 24.92% | 20.48% | 9.58% | 21.44% |
| Depreciation & Amortization | -357.90% | 543.75% | 551.02% | -12.15% | 39.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.12% | 62.91% | 64.01% | -15.85% | 47.74% |
| Operating Income | 38.30% | -70.64% | -81.86% | 15.38% | -124.84% |
| Income Before Tax | 3.65% | -59.47% | -26.79% | 11.22% | -54.72% |
| Income Tax Expenses | -769.08% | -8.05% | -50.58% | 73.41% | 4.41% |
| Earnings from Continuing Operations | 27.44% | -78.63% | -20.97% | -1.25% | -57.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.44% | -78.63% | -20.97% | -1.25% | -57.73% |
| EBIT | 38.30% | -70.64% | -81.86% | 15.38% | -124.84% |
| EBITDA | 55.50% | -15.44% | -24.36% | 15.68% | -143.91% |
| EPS Basic | 28.69% | -75.40% | -18.73% | 0.50% | -55.56% |
| Normalized Basic EPS | 46.62% | -97.76% | -18.37% | 2.96% | -179.72% |
| EPS Diluted | 31.80% | -73.30% | -18.18% | 0.00% | -62.64% |
| Normalized Diluted EPS | 46.62% | -97.76% | -18.37% | 2.96% | -179.72% |
| Average Basic Shares Outstanding | 1.76% | 1.85% | 1.84% | 1.72% | 1.43% |
| Average Diluted Shares Outstanding | 1.76% | 1.85% | 1.84% | 1.72% | 1.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |